Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation
- Zachariah DeFilipp1, †, Nalu Navarro-Alvarez2, 3, 4, †, Shuli Li5, Alec R. Andrews2, Ariel Johnson7, Yi-Bin Chen1, Vincent T. Ho6, Jerome Ritz6, Thomas R. Spitzer1, Christene A. Huang2, 7, *1 Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA2 Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA3 Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico4 Departamento de Biología Molecular, Universidad Panamericana, Escuela de Medicina, CDMX, Mexico5 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA6 Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA7 Department of Surgery, Division of Plastic & Reconstructive Surgery, Division of Transplant Surgery, University of Colorado School of Medicine, Aurora, CO†
Both authors contributed equally to this work.*Corresponding author. Email: firstname.lastname@example.org
- Corresponding Author
- Christene A. Huang
- https://doi.org/10.2991/chi.d.190823.001How to use a DOI?
- Galectin-3, Chronic graft-versus-host disease, Allogeneic hematopoietic cell transplantation
Galectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD). Plasma galectin-3 concentrations were measured at 1 year post-HCT and correlated with clinical data collected from individual medical records. The median serum galectin-3 level at that time point was 14.9 ng/mL (range, 5.5–61.6), which was significantly higher than that among healthy controls (14.9 versus 6.2, p < 0.001). Furthermore, patients with active cGVHD at the time of sample collection had higher median levels as compared to those without cGVHD (16.9 versus 13, p = 0.03). In a multivariable logistic model, there was no significant association between the presence of cGVHD at the date of sample collection and elevated galectin-3 levels (>14.9 ng/mL) (odds ratio [OR]: 2.03 (0.60, 6.88), p = 0.26). However, among patients with cGVHD at the date of sample collection, active systemic corticosteroid therapy was associated with elevated galectin-3 levels (OR: 20.32 (1.66, 249.39), p = 0.02). Furthermore, in a competing risk regression model, elevated galectin-3 levels at 1 year post-HCT were not associated with future development of moderate or severe cGVHD (OR: 1.24 (0.21, 7.45), p = 0.81). In conclusion, plasma galectin-3 concentrations are elevated in recipients of allo-HCT, especially among patients with cGVHD. Further investigation will be required to determine whether galectin-3 has a pathophysiologic role in cGVHD or serves as a marker of ongoing inflammation following allogeneic HCT.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Zachariah DeFilipp AU - Nalu Navarro-Alvarez AU - Shuli Li AU - Alec R. Andrews AU - Ariel Johnson AU - Yi-Bin Chen AU - Vincent T. Ho AU - Jerome Ritz AU - Thomas R. Spitzer AU - Christene A. Huang PY - 2019 DA - 2019/08 TI - Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation JO - Clinical Hematology International SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.190823.001 DO - https://doi.org/10.2991/chi.d.190823.001 ID - DeFilipp2019 ER -